366 related articles for article (PubMed ID: 10409398)
1. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines.
Taatjes DJ; Koch TH
Anticancer Res; 1999; 19(2A):1201-8. PubMed ID: 10368676
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
Burke PJ; Koch TH
Anticancer Res; 2001; 21(4A):2753-60. PubMed ID: 11724351
[TBL] [Abstract][Full Text] [Related]
4. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
Taatjes DJ; Fenick DJ; Koch TH
J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
[TBL] [Abstract][Full Text] [Related]
5. Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
Fenick DJ; Taatjes DJ; Koch TH
J Med Chem; 1997 Aug; 40(16):2452-61. PubMed ID: 9258351
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of epidoxorubicin-formaldehyde virtual crosslink of DNA and evidence for its formation in human breast-cancer cells.
Podell ER; Harrington DJ; Taatjes DJ; Koch TH
Acta Crystallogr D Biol Crystallogr; 1999 Sep; 55(Pt 9):1516-23. PubMed ID: 10489446
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs.
Kato S; Burke PJ; Fenick DJ; Taatjes DJ; Bierbaum VM; Koch TH
Chem Res Toxicol; 2000 Jun; 13(6):509-16. PubMed ID: 10858324
[TBL] [Abstract][Full Text] [Related]
8. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells.
Taatjes DJ; Koch TH
Curr Med Chem; 2001 Jan; 8(1):15-29. PubMed ID: 11172689
[TBL] [Abstract][Full Text] [Related]
9. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.
Inaba M; Kobayashi H; Sakurai Y; Johnson RK
Cancer Res; 1979 Jun; 39(6 Pt 1):2200-3. PubMed ID: 445418
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering?
Serafino A; Sinibaldi-Vallebona P; Pierimarchi P; Bernard P; Gaudiano G; Massa C; Rasi G; Ranagnan G
Anticancer Res; 1999; 19(3A):1909-18. PubMed ID: 10470135
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
13. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM
Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435
[TBL] [Abstract][Full Text] [Related]
14. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms.
Serafino A; Sinibaldi-Vallebona P; Gaudiano G; Koch TH; Rasi G; Garaci E; Ravagnan G
Anticancer Res; 1998; 18(2A):1159-66. PubMed ID: 9615782
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues.
Chambers SK; Hait WN; Kacinski BM; Keyes SR; Handschumacher RE
Cancer Res; 1989 Nov; 49(22):6275-9. PubMed ID: 2804973
[TBL] [Abstract][Full Text] [Related]
17. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Burke PJ; Koch TH
J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
[TBL] [Abstract][Full Text] [Related]
19. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activity, accumulation, and intracellular distribution of anthracycline antibiotics and their conjugates with the epidermal growth factor in sensitive and resistant MCF-7 cells.
Lutsenko SV; Feldman NB; Gumanov SG; Rodina AV; Severin SE
Biochemistry (Mosc); 2000 Nov; 65(11):1299-304. PubMed ID: 11112847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]